What is the management plan for a patient with impaired clot formation, as indicated by low Max Amplitude and Functional Fibrinogen (Fibrinogen) MA on thromboelastography (TEG) results, and hypofibrinogenemia (low fibrinogen level)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 2, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Management of Low TEG Max Amplitude and Functional Fibrinogen MA

Immediate Fibrinogen Replacement is Required

Your patient has critical hypofibrinogenemia with impaired clot formation requiring immediate fibrinogen replacement with either fibrinogen concentrate (3-4 grams) or cryoprecipitate (50 mg/kg, approximately 15-20 single donor units in a 70 kg adult). 1

Interpretation of Your TEG Results

Your TEG demonstrates a functional fibrinogen deficit:

  • Rapid TEG Max Amplitude of 49 mm (Low): Indicates overall impaired clot strength 2, 3
  • Functional Fibrinogen MA of 22 mm (Low): This is critically low and correlates with plasma fibrinogen levels well below the 1.5-2.0 g/L threshold required for adequate hemostasis 1, 3
  • Normal Reaction Time (6.2-7.7 min): Suggests preserved thrombin generation, meaning the primary defect is fibrinogen, not clotting factor deficiency 1

The functional fibrinogen MA of 22 mm is particularly concerning, as this represents severe hypofibrinogenemia requiring urgent correction. 3, 4

Step-by-Step Management Algorithm

1. Immediate Fibrinogen Replacement

  • First-line therapy: Administer fibrinogen concentrate 3-4 grams IV OR cryoprecipitate 50 mg/kg (15-20 units for 70 kg patient) 1
  • Target: Achieve fibrinogen level ≥1.5-2.0 g/L or functional fibrinogen MA >9 mm on repeat TEG 1
  • Rationale: Fibrinogen is the first coagulation factor to critically decrease during bleeding, and your patient's functional fibrinogen MA of 22 mm indicates severe depletion 1, 5

2. Repeat TEG After Fibrinogen Replacement

  • Recheck TEG 15-30 minutes after fibrinogen administration 3, 4
  • If functional fibrinogen MA remains <9 mm: Give additional fibrinogen (repeat dosing guided by TEG) 1
  • If functional fibrinogen MA normalizes but overall MA remains low: Consider platelet transfusion, as platelets contribute approximately 70% to clot strength 2, 3

3. Assess for Additional Coagulation Factor Deficiency

  • Only if fibrinogen level is normalized (>1.5 g/L or functional fibrinogen MA >9 mm) AND reaction time remains prolonged: Consider prothrombin complex concentrate (PCC) for factor deficiency 1
  • Do NOT give PCC first: Your normal reaction time indicates preserved thrombin generation; fibrinogen is the primary deficit 1

4. Monitor for Bleeding and Transfusion Requirements

  • **If active bleeding with platelet count <50 × 10⁹/L**: Transfuse platelets to maintain >50 × 10⁹/L 1
  • If massive transfusion anticipated: Maintain plasma:RBC ratio of 1:2 to 3:4 alongside fibrinogen replacement 1

Critical Thresholds to Remember

  • Fibrinogen <1.5 g/L (or functional fibrinogen MA <9 mm): Immediate replacement required 1
  • Fibrinogen <2.0 g/L: Associated with 100% positive predictive value for severe hemorrhage progression 1, 5
  • Functional fibrinogen MA <22 mm: Your patient is at this critical threshold requiring urgent intervention 3

Common Pitfalls to Avoid

Do Not Rely on PT/INR Alone

  • Conventional coagulation screens (PT/INR, aPTT) only monitor coagulation initiation and may appear normal while fibrinogen is critically depleted 5
  • Your patient's reaction time is normal, which could falsely reassure if you ignore the functional fibrinogen deficit 5

Do Not Delay for Laboratory Fibrinogen Results

  • TEG functional fibrinogen provides real-time assessment with 30-60 minute time savings over Clauss fibrinogen 5, 4
  • Act on the TEG results immediately rather than waiting for laboratory confirmation 5

Do Not Overuse PCC

  • PCC is only indicated if fibrinogen is normal AND reaction time is prolonged 1
  • Inappropriate PCC use increases thrombotic risk without addressing the primary fibrinogen deficit 1

Avoid Artificial Colloids

  • Hydroxyethyl starch (HES) causes laboratory fibrinogen assays to overestimate actual levels and should be avoided 1, 6, 5

Monitoring Response to Treatment

  • Repeat TEG every 30-60 minutes until functional fibrinogen MA >9 mm and overall MA >50 mm 1, 4
  • Target functional fibrinogen MA: 9-14 mm (avoid exceeding 14 mm to prevent thrombotic complications) 1
  • Clinical endpoints: Cessation of microvascular bleeding, improved hemostasis 1

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Fibrinogen Measurement in Hemorrhagic CVA

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Management of Elevated Fibrinogen Levels

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Related Questions

What does a low Maximum Amplitude (MA) on Thromboelastography (TEG) indicate?
What is the recommended treatment to correct high K time on Thromboelastography (TEG)?
What is 149 milligrams per deciliter (mg/dL) of fibrinogen in grams per liter (g/L)?
What is the interpretation of an elevated Thromboelastography (TEG) alpha angle and elevated Functional Fibrinogen (CFF-MA) and Functional Fibrin (CFF-FLEVT) values?
What is the mechanism of Thromboelastography (TEG)?
What is the management approach for a patient with platelet clumping, considering underlying causes and potential thrombotic events?
What is the recommended amount and timing of blood transfusion for a 50-year-old male patient with a preoperative hemoglobin (Hb) level of 13.0 g/dL who experienced 2500 ml of blood loss during a revision right total hip replacement (THR) surgery?
What is the recommended approach for a comprehensive musculoskeletal assessment and management of back pain in an adult patient?
Is it safe to prescribe gabapentin (Neurontin) to older adults at risk for dementia, considering studies suggest gabapentinoids do not cause dementia?
Can a female patient of reproductive age taking hormonal medications, such as contraceptives (birth control) or hormone replacement therapy (HRT), experience irregular withdrawal bleed patterns?
How do you differentiate between serotonin syndrome and neuroleptic malignant syndrome in a patient presenting with agitation, confusion, and muscle rigidity, with a history of taking antidepressants (e.g. selective serotonin reuptake inhibitors (SSRIs)) and antipsychotics?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.